Harnessing a continuous perfusion process for improved productivity
Introduction
Continuous perfusion allows for the constant feeding of fresh media into a bioreactor while removing used media. This means that the cell environment maintains consistency, helping to boost growth, viability, and productivity.
As a result, the global perfusion bioreactors market is predicted to grow from $355.6 million in 2022 to reach 747.6 million by the end of 2033 at a compound annual growth rate of 7.2%1.
Why did the customer approach Enzene?
A client approached Enzene biosciences, struggling to run a fed-batch beyond 10 days, which only produced a very low titer of 600 to 700mg when cultured.
Enzene’s approach
The batch was first reproduced leveraging the client’s media, feed, and process strategy on fed-batch. Having analyzed the process when using the original conditions, the media and feed were replaced with Enzene’s platform, redefining the fed-batch process strategy.
The process was optimized, starting from a small 250mL Ambr scale through to a 2KL bioreactor and vice versa for verification, and production was transitioned to a perfusion process. This perfusion process utilized less feed (1%) than a fed-batch (5 to 10%), harnessing around 20 to 25 pg per cell per day.
Outcomes
Therefore, productivity was significantly improved when adopting Enzene’s continuous perfusion
manufacturing solution.
The successful introduction of Enzene’s fed-batch strategy led to an 8x improvement in productivity (4500mg/titre), with the transition to a continuous perfusion manufacturing process resulting in an 8x further productivity improvement.
1 Global Perfusion Bioreactors Market, accessed 8 February 2024, from: https://www.globenewswire.com/en/news-release/2023/08/17/2727371/0/en/Global-Perfusion-Bioreactors-Market-to-Reach-US-747-6-Million-by-2033-Surge-in-Biopharmaceutical-Production-Drives-Growth-Persistence-Market-Research.html#:~:text=New%20York%2C%20Aug.,by%20the%20end%20of%202033.
Related resources
Related CDMO solutions
Join the revolution
Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.